Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label phase 2 study analyzing safety and efficacy of VIR-2218 with or without Peginterferon-alfa non-cirrhotic, virally-suppressed adults with chronic HBV infection

Next Previous
Trial Profile

An open-label phase 2 study analyzing safety and efficacy of VIR-2218 with or without Peginterferon-alfa non-cirrhotic, virally-suppressed adults with chronic HBV infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elebsiran (Primary) ; Peginterferon alfa
  • Indications Hepatitis B
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 24 Jun 2023 Results assessing safety and efficacy follow-up data of VIR-2218 with or without PEG-IFNa at least 24 weeks post-end oftreatment (EOT) presented at the European Association for the Study of the Liver Congress 2023
  • 27 Dec 2022 New trial record
  • 08 Nov 2022 Results presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top